N-Power Medicine, a trailblazer in redefining the clinical trial landscape, has announced a significant milestone with the closure of its Series B funding round, securing $72 million in total funding. Led by the Merck Global Health Innovation Fund, alongside a prominent U.S.-based healthcare investor, this funding infusion marks a pivotal moment for N-Power Medicine as it aims to expand its network of oncology clinics and bolster collaborations with biopharmaceutical companies. The investment will further support N-Power’s pioneering platform, designed to seamlessly integrate clinical research into routine patient care.
Founded in 2021 by Dr. Mark Lee, M.D., Ph.D., N-Power Medicine endeavors to revolutionize the drug development process by accelerating timelines and enhancing access to cutting-edge therapies for cancer patients. Dr. Lee, Co-Founder and CEO of N-Power, highlighted the company’s vision to democratize clinical trials, stating, “Our mission is to drastically shorten the path from drug development to patient access. By empowering every oncologist and patient to participate in advancing drug development, we believe we can make a profound impact on patient outcomes.”
The cornerstone of N-Power’s innovation lies in its integrated data platform, which streamlines both clinical trial operations and routine patient management. The platform, known as Kaleido™ Registry, has already enrolled over 7,000 patients, collecting real-time, standardized data crucial for clinical research and drug development. This approach not only accelerates the identification of trial-eligible patients but also provides invaluable insights that inform the design of future trials.
David M. Rubin, Ph.D., Managing Director of Merck Global Health Innovation Fund, underscored the strategic importance of partnering with N-Power Medicine. “N-Power’s platform offers a unique opportunity to expand the reach of clinical research, enabling more oncologists and patients to participate in transformative drug development efforts,” said Rubin. “We are committed to supporting innovations that enhance patient care and drive efficiencies in biopharmaceutical operations.”
Editorial Opinion: Accelerating Innovation in Oncology Clinical Trials
The recent Series B funding round for N-Power Medicine marks a significant stride towards revolutionizing oncology clinical trials. With oncology drug development traditionally spanning a decade, N-Power’s integrated platform aims to slash timelines and democratize access to clinical trials. By embedding research capabilities within routine patient care, N-Power empowers oncologists to harness the full potential of patient data, facilitating quicker, more informed decision-making in drug development.
In the competitive landscape of biopharmaceuticals, where innovation is paramount, N-Power’s approach addresses critical gaps in clinical trial accessibility and efficiency. By leveraging advanced technology and expert support, N-Power not only accelerates the pace of research but also ensures that oncologists can focus more on patient care rather than administrative burdens. This funding round not only validates N-Power’s innovative model but also signals a promising future in advancing oncology treatment options.
For further inquiries or corrections, please contact editor@thetimesmag.com.
